# Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

> **NCT02180503** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1356 BS PIB - low dose
- **DRUG:** BI 1356 BS tablet - low dose
- **DRUG:** BI 1356 BS PIB - high dose
- **DRUG:** BI 1356 BS tablet - high dose
- **DRUG:** BI 1356 BS tablet - high dose with food

## Key facts

- **NCT ID:** NCT02180503
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2005-10
- **Final completion:** —
- **Target enrollment:** 24 (—)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180503, "Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02180503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*